Article

Decreased production of vascular endothelial growth factor in adriamycin-resistant breast cancer cells.

College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.
Cancer letters (impact factor: 4.86). 06/2008; 268(2):225-32. DOI:10.1016/j.canlet.2008.03.050
Source: PubMed

ABSTRACT MCF-7/ADR cells, a doxorubicin-resistant human breast cancer cell line, have acquired resistance to several anti-cancer chemotherapeutic agents, such as anthracyclines and taxol. Here, we found that MCF-7/ADR cells produced lower levels of vascular endothelial growth factor (VEGF) than control MCF-7 cells. Molecular analyses using Western blots and reporter constructs containing either the human VEGF promoter or a minimal promoter for the transcription factor, hypoxia-inducible factor-1 (HIF-1), supported the involvement of HIF-1alpha in the down-regulation of VEGF transcription in MCF-7/ADR cells. In addition, the basal activities of Akt and GSK-3beta were deregulated in MCF-7/ADR cells, and either the activation of PI3-kinase or the inhibition of GSK-3 restored the diminished transcription of VEGF. Chick chorioallantoic membrane (CAM) assay finally confirmed that angiogenesis intensity in MCF-7/ADR cells was significantly decreased compared with that in control MCF-7 cells.

0 0
 · 
0 Bookmarks
 · 
35 Views

Keywords

activation
 
angiogenesis intensity
 
anti-cancer chemotherapeutic agents
 
CAM
 
Chick chorioallantoic membrane
 
control MCF-7 cells
 
diminished transcription
 
doxorubicin-resistant human breast cancer cell line
 
GSK-3beta
 
human VEGF promoter
 
hypoxia-inducible factor-1
 
inhibition
 
MCF-7/ADR cells
 
minimal promoter
 
reporter constructs
 
vascular endothelial growth factor
 
VEGF
 
VEGF transcription
 
Western blots
 

Jung-Ae Kim